Phase 1 study of ropidoxuridine for Increasing gastrointestinal cancer radiation sensitivity

For this open label, dose-escalation phase 1 study, researchers are assessing the toxicity profile and efficacy of ropidoxuridine in patients with metastatic gastrointestinal cancer unlikely to respond to radiation. Ropidoxuridine may sensitise cancer cells to radiotherapy.
Cancer Therapy Advisor